Os testes moleculares podem solucionar o problema nos nódulos de tireoide indefinidos na PAAF?

Abstract

Introduction: Thyroid cancer is the most common type of cancer in the head and neck region. After aspiration identification for cytological examination due to its ultrasound features, assessment of fine needle aspirates (FNA) for cyto examination. This is currently assessed by the Bethesda classification which identifies 20 to 30% of the Bethesda classification criteria as undetermined (Bethesda III and IV). Many patients with indeterminate nodules undergo thyroidectomy, but histological reports indicate that up to 84% of Bethesda III and IV cases are benign, generating a high rate of unnecessary surgeries.In this review article we will evaluate Methodology: Articles were selected from PubMed and Clinicalkey databases using titles and abstracts for potential articles. Results and Discussion: Were and ThyroidPrint adhered to these available molecular data: Affirms G, RosettaGX v2 and v3, RosettaGXveal, Mir-THYpe and ThyroidPrint, their applications, benefits and use. Conclusion: Molecular thyroid tests have evolved a lot, but still have some recent molecular tests, such as unproduced and high-cost genetic abnormalities. For its use to be justified, the molecular test must be able to significantly alter the prognosis and clinical management. The tendency is that, with the evolution of the quality of the tests and the reduction of production costs, its use in the practice of cytopathology of thyroid nodules will be expanded.